Doxium as oral medication for Diabetic Retinopathy in Scrip, August 23rd, 2006

August 30th, 2006. … “Additional studies might be needed before the drug (Arxxant from Lilly) can make it onto the market…. One product Arxxant will have to compete with is OM PHARMA’s Doxium (calcium dobesilate), which is available for the treatment of diabetic retinopathy, and was shown in a two-year study to slow disease progression. The primary endpoint of posterior vitreous penetration ratio, measured by fluorophotometry in order to evaluate vascular leakage from the retina, showed a decrease of 13.2% in the Doxium group versus a 7.3% increase with placebo (p=0.002), whether the patients’ diabetes was well controlled or not.”…